Lorlatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LORLATINIB |
|---|---|
| Type | Drug |
| Aliases | LorbrenaЛорлатініб |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 3rd-generation ALK / ROS1 inhibitor |
|---|---|
| Mechanism | Macrocyclic ALK/ROS1 TKI with activity vs nearly all ALK resistance mutations + excellent CNS penetration. CROWN: superior PFS vs crizotinib 1L (3-year PFS rate 64% lorlatinib vs 19% crizotinib). |
| Typical dosing | 100 mg PO once daily. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
CROWN trial: most active ALK TKI to date, with 3-year PFS exceeding any prior ALK 1L. Cognitive AE profile distinct — careful patient selection. Effective for post-alectinib resistance.
Used By
Regimens
REG-LORLATINIB-NSCLC- Lorlatinib monotherapy (ALK+ NSCLC, 1L OR post-2G TKI)